| Description | The isolated murine anti-TweakR agonist antibody 136.1 demonstrates high agonist activity. It inhibits cancer cell growth by inducing apoptosis through caspase activation. 136.1 can induce apoptosis through caspase activation in HT29. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Immunogen | Mouse 3T12 cells overexpressing human TweakR |
| Neutralization Mechanism | The antibody inhibits the growth of the cancer cells by inducing apoptosis through caspasc activation |
| Affinity | KD = 0.68 nM |
| Isotype | Mouse IgG |
| Expression Species | HEK293F or CHO |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein G affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | Agonist |
| Application Notes | Agonist: 10 μg/mL |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TNFRSF12A |
| Alternative Name | TNF Receptor Superfamily Member 12A; Fibroblast Growth Factor-Inducible Immediate-Early Response Protein 14; FGF-Inducible 14; Tweak-Receptor; TWEAKR; FN14 |
| Gene ID | 51330 |
| UniProt | Q9NP84 |
| Related pathway | Apoptotic signaling pathway |
| Research Area | Cancer Research; Signal Pathway |
| Related Disease | Bladder cancer, Breast cancer, Colorectal cancer, Lung cancer, Melanoma, Pancreatic cancer, Head and neck cancer, Ovarian cancer, Stomach cancer, Uterine cancer, Cervical cancer, Esophageal cancer, Renal cell carcinoma, Glioblastoma, and Sarcomas |
